Transcode Therapeutics Inc (RNAZ) - Cash Flow Conversion Efficiency
Based on the latest financial reports, Transcode Therapeutics Inc (RNAZ) has a cash flow conversion efficiency ratio of -0.788x as of March 2026. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($-8.14 Million) by net assets ($10.34 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. See RNAZ equity financing ratio to measure how much of total assets are equity-financed.
Transcode Therapeutics Inc - Cash Flow Conversion Efficiency Trend (2018–2025)
This chart illustrates how Transcode Therapeutics Inc's cash flow conversion efficiency has evolved over time, based on yearly financial data. Check Transcode Therapeutics Inc cash flow quality index to evaluate the quality of earnings relative to operating cash generation.
Transcode Therapeutics Inc Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Transcode Therapeutics Inc ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
State GAS Ltd
AU:GAS
|
-0.031x |
|
Inhalerx Ltd
AU:IRX
|
-0.033x |
|
Desert Control AS
OL:DSRT
|
-0.415x |
|
Merino & Co. Ltd
AU:MNC
|
-0.297x |
|
ASIA Capital Group Public Company Limited
BK:ACAP
|
0.032x |
|
TAIZHOU WATER GRP. H YC 1
F:GX5
|
N/A |
|
Zeb Nickel Corp
V:ZBNI
|
0.003x |
|
Sulliden Minerals SA
TO:SMC
|
0.090x |
Annual Cash Flow Conversion Efficiency for Transcode Therapeutics Inc (2018–2025)
The table below shows the annual cash flow conversion efficiency of Transcode Therapeutics Inc from 2018 to 2025. For the full company profile with market capitalisation and key ratios, see RNAZ market cap.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-12-31 | $10.34 Million | $-19.52 Million | -1.888x | -128.58% |
| 2024-12-31 | $-2.02 Million | $-13.34 Million | 6.606x | +159.97% |
| 2023-12-31 | $1.64 Million | $-18.07 Million | -11.016x | -126.48% |
| 2022-12-31 | $3.24 Million | $-15.76 Million | -4.864x | -1784.33% |
| 2021-12-31 | $20.40 Million | $-5.27 Million | -0.258x | -278.46% |
| 2020-12-31 | $-3.41 Million | $-492.97K | 0.145x | -68.78% |
| 2019-12-31 | $-1.10 Million | $-508.51K | 0.463x | -22.05% |
| 2018-12-31 | $-503.97K | $-299.57K | 0.594x | -- |
About Transcode Therapeutics Inc
TransCode Therapeutics, Inc., a biopharmaceutical company, focuses on developing and commercializing drugs and diagnostics for treating and identifying cancer. The company's lead therapeutic candidate comprises TTX-MC138 that targets microRNA-10b, a master regulator of metastatic cell viability in various cancers comprising breast, pancreatic, ovarian, colon cancer, glioblastomas, and others. Its… Read more